Surrozen (SRZN) Capital Expenditures (2020 - 2026)
Surrozen (SRZN) posted quarterly Capital Expenditures of $120000.0 for Q1 2026, up 344.44% year-over-year from $27000.0 in Q1 2025, and up 103.39% quarter-over-quarter from $59000.0 in Q4 2025.
Surrozen (SRZN) Capital Expenditures (2020 - 2026) Analysis & Trends
Surrozen's Capital Expenditures history runs 7 years deep, the most recent figure standing at $120000.0 for Q1 2026.
- In Q1 2026, Capital Expenditures rose 344.44% year-over-year to $120000.0; the TTM figure through Mar 2026 stood at $221000.0 (up 662.07% YoY), while the FY2025 annual figure was $128000.0, up 1322.22% from the prior year.
- Capital Expenditures for Q1 2026 stood at $120000.0, up from $59000.0 in the prior quarter.
- The five-year high for Capital Expenditures was $412000.0 in Q1 2022, with the low at -$426000.0 in Q3 2022.
- The 5-year median for Capital Expenditures is $27000.0 (2025), against an average of $56923.1.
- The sharpest annual moves came in 2022 and 2025: Capital Expenditures plunged 117.35% in 2022, then jumped 2850.0% in 2025.
- Surrozen's Capital Expenditures stood at $76000.0 in 2022, then advanced by 9.21% to $83000.0 in 2023, then plunged by 97.59% to $2000.0 in 2024, then surged by 2850.0% to $59000.0 in 2025, then soared by 103.39% to $120000.0 in 2026.
- Business Quant data shows SRZN's Capital Expenditures at $120000.0 in Q1 2026, $59000.0 in Q4 2025, and $24000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Surrozen | 281.63 Mn | 281.63 Mn | - | 19,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 19,000.00 |
| Jun 30, 2026 | 19,000.00 |
| Mar 31, 2026 | 120,000.00 |
| Mar 31, 2026 | 120,000.00 |
| Dec 31, 2025 | 59,000.00 |
| Dec 31, 2025 | 59,000.00 |
| Sep 30, 2025 | 24,000.00 |
| Sep 30, 2025 | 24,000.00 |
| Jun 30, 2025 | 18,000.00 |
| Jun 30, 2025 | 18,000.00 |
| Mar 31, 2025 | 27,000.00 |
| Mar 31, 2025 | 27,000.00 |
| Dec 31, 2024 | 2,000.00 |
| Dec 31, 2024 | 2,000.00 |
| Mar 31, 2024 | 7,000.00 |
| Mar 31, 2024 | 7,000.00 |
| Jun 30, 2023 | 83,000.00 |
| Jun 30, 2023 | 83,000.00 |
| Mar 31, 2023 | 315,000.00 |
| Mar 31, 2023 | 315,000.00 |